BCM
ELDN icon

Bayesian Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Bayesian Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-645
Closed -$5K – 561
2020
Q2 		$5K Buy
+645
New +$7.28K ﹤0.01% 502

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Bayesian Capital Management's ELDN Position: Q3 2020 in Review

Bayesian Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2020, closing a stake of 645 shares — an estimated $5K sold.

Bayesian Capital Management first reported a position in ELDN in Q2 2020 and held it in 1 quarter. The position peaked at $5K in Q2 2020. 19 funds tracked by Wall St. Rank hold ELDN as of Q3 2020.

  • Bayesian Capital Management reported no remaining Eledon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 645 Eledon Pharmaceuticals shares in Q3 2020, an estimated $5K.
  • Bayesian Capital Management first reported a position in Eledon Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Bayesian Capital Management's Eledon Pharmaceuticals position peaked at $5K in Q2 2020.
  • 19 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2020.

Based on Bayesian Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.